Afuco™ Anti-C5 ADCC Therapeutic Antibody (Eculizumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to Human C5. Eculizumab also is the first agent approved for the treatment of atypical hemolytic uremic syndrome (aHUS), an ultra-rare genetic disease that causes abnormal blood clots to form in small blood vessels throughout the body, leading to kidney failure, damage to other vital organs and premature death.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-008 |
| Pricing | Inquiry |
| Host | Human |
| Target | C5 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | ELISA, FC, IP, FuncS, IF, Neut |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |